P
Peter Goedings
Publications - 8
Citations - 184
Peter Goedings is an academic researcher. The author has contributed to research in topics: Trastuzumab & In vivo. The author has an hindex of 4, co-authored 8 publications receiving 142 citations.
Papers
More filters
Journal ArticleDOI
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
Miranda M.C. van der Lee,Patrick G. Groothuis,Ruud Ubink,Monique van der Vleuten,Tanja van Achterberg,Eline Loosveld,Desiree Damming,Danielle Jacobs,Myrthe Rouwette,David F. Egging,Diels van den Dobbelsteen,Patrick Henry Beusker,Peter Goedings,GF Verheijden,Jacques M. Lemmens,Marco Timmers,Wim H. A. Dokter +16 more
TL;DR: In vivo antitumor studies in breast cancer PDX models showed that SYD985 is very active in HER2 3+, 2+, and 1+ models, whereas T-DM1 only showed significant antitumors activity in HER 2 3+ breast cancerPDX models.
Journal ArticleDOI
Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC).
Gijs Verheijden,Patrick Beusker,Ruud Ubink,Miranda van der Lee,Patrick G. Groothuis,Peter Goedings,David F. Egging,Ellen Mattaar,Macro Timmers,Wim H. A. Dokter +9 more
TL;DR: This paper describes the direct comparison of SYD985 to T-DM1 (ado-trastuzumab emtansine) in vitro and in vivo and shows similar potencies and activities.
Proceedings ArticleDOI
Abstract 4329: Novel HER2 targeting antibody-drug conjugates based on DNA-interacting duocarmycin and an unique linker technology with great potential in breast cancer and NSCLC.
Wim H. A. Dokter,Patrick Beusker,Gijs Verheijden,Ruud Ubink,Miranda van der Lee,Diels van den Dobbelsteen,Peter Goedings,Jacques M. Lemmens,Vincent F.M.H. De Groot,Marco Timmers +9 more
TL;DR: It is concluded that a new class of HER2-based ADCs that have great potential to become effective treatment for Her2-positive tumors, including breast cancer and NSCLC are generated.
Proceedings ArticleDOI
Abstract 2652:In vitroandin vivoantitumor activity of SYD985, a novel HER2-targeting ADC: a comparison with T-DM1
Willem Dokter,Miranda van der Lee,Patrick G. Groothuis,Tanja van Achterberg,Eline Loosveld,Danielle Jacobs,Monique van der Vleuten,Patrick Beusker,Leon Hooftman,Peter Goedings,Gijs Verheijden,Marco Timmers +11 more
TL;DR: SYD985 is more potent than T-DM1, both in vitro and in vivo in all responsive models, and the potency advantage of SYD985 over T- DM1 is enhanced even further in the tumor cell lines and PDX models with low HER2 expression.
Proceedings ArticleDOI
Abstract P4-15-14: Preclinical data of SYD985 support the clinical investigation of this novel anti-HER2 antibody-drug conjugate in breast cancer patients with low levels of HER2 expression
Gijs Verheijden,Patrick Beusker,Ruud Ubink,Miranda van der Lee,Patrick G. Groothuis,Peter Goedings,David F. Egging,Marco Timmers,Wim H. A. Dokter +8 more
TL;DR: Preclinical data of SYD985 support the clinical investigation of this novel anti-HER2 antibody-drug conjugate in breast cancer patients with low levels of HER2 expression, and Pharmacokinetic experiments have revealed that whereas in mice SYd985 has limited stability, in cynomolgus monkey SYD990 is very stable.